Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Receivables for 11 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 11.17% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 11.17% increase, with the full-year FY2025 number at $9.5 million, up 11.17% from a year prior.
  • Receivables was $9.5 million for Q4 2025 at Intellia Therapeutics, down from $11.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $37.5 million in Q4 2023 to a low of $1.8 million in Q1 2022.
  • A 5-year average of $9.4 million and a median of $7.0 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 91.03% in 2021, then surged 599.71% in 2024.
  • Intellia Therapeutics' Receivables stood at $2.1 million in 2021, then soared by 151.9% to $5.4 million in 2022, then surged by 597.76% to $37.5 million in 2023, then plummeted by 77.26% to $8.5 million in 2024, then grew by 11.17% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Receivables are $9.5 million (Q4 2025), $11.0 million (Q3 2025), and $11.4 million (Q2 2025).